William Blair Predicts DexCom's Q1 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM - Free Report) - William Blair decreased their Q1 2025 earnings per share (EPS) estimates for DexCom in a report released on Monday, March 10th. William Blair analyst M. Andrew now forecasts that the medical device company will earn $0.33 per share for the quarter, down from their previous forecast of $0.34. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom's Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.64 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.58 EPS, Q3 2026 earnings at $0.69 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.43 EPS.

DXCM has been the subject of a number of other reports. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and a consensus price target of $99.82.

Remove Ads

DexCom Price Performance

Shares of NASDAQ DXCM opened at $70.26 on Wednesday. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a 50 day moving average price of $84.53 and a two-hundred day moving average price of $76.98. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The firm has a market cap of $27.46 billion, a PE ratio of 49.13, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 45,083 shares of company stock worth $3,826,604. 0.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Forvis Mazars Wealth Advisors LLC boosted its position in DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. grew its position in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after purchasing an additional 135 shares during the period. Larson Financial Group LLC grew its position in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the period. Nia Impact Advisors LLC grew its position in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after acquiring an additional 140 shares during the period. Finally, Level Four Advisory Services LLC grew its position in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares during the period. Institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.